The History of GLP-1 Research: From Discovery to Triple Agonists

The history of GLP-1 research spans more than four decades of work in endocrinology, molecular biology, and metabolic physiology. Glucagon-like peptide-1, commonly abbreviated GLP-1, emerged from research into how the gut signals the pancreas after a meal. Tracing the history of GLP-1 research helps illustrate how a single peptide hormone became one of the most studied targets in metabolic science, eventually informing the development of multi-receptor compounds such as triple agonists. This article reviews that history from a research and literature perspective, with all compounds discussed for laboratory study only.

Early Foundations of Incretin Science

The conceptual roots of GLP-1 research lie in the incretin hypothesis. Researchers in the early twentieth century observed that orally administered glucose produced a larger insulin response than glucose delivered intravenously. This observation suggested that the gut released factors, later termed incretins, that amplified pancreatic insulin secretion. Studies through the mid twentieth century worked to identify the molecular basis of this so-called incretin effect.

The first incretin to be characterized in research was gastric inhibitory polypeptide, later renamed glucose-dependent insulinotropic polypeptide, or GIP. While GIP accounted for part of the incretin effect observed in studies, researchers found that it did not explain the full magnitude of the response. This gap motivated the search for a second incretin hormone.

The Discovery of GLP-1

GLP-1 was identified in the 1980s through molecular cloning of the proglucagon gene. Researchers found that the proglucagon precursor was processed differently in the intestine than in the pancreas, yielding several peptides including GLP-1. Early studies of the full-length peptide showed limited activity, but subsequent research demonstrated that a truncated form was a potent stimulator of glucose-dependent insulin secretion in laboratory models.

This finding was pivotal in the history of GLP-1 research. It established GLP-1 as the long-sought second incretin and opened a broad program of investigation into its physiology. Studies examined how GLP-1 was secreted from intestinal L-cells in response to nutrients and how it acted on the GLP-1 receptor, a member of the G protein-coupled receptor family expressed in pancreatic tissue and other sites.

Characterizing GLP-1 Physiology in Research

Through the 1990s, research mapped a range of effects attributed to GLP-1 receptor signaling in study models. These included glucose-dependent modulation of insulin secretion, effects on glucagon release, influence on gastric emptying, and central nervous system signaling associated with satiety pathways. Researchers exploring these mechanisms noted that GLP-1 activity appeared to be glucose-dependent, a property of significant interest in metabolic literature.

A central challenge identified in this period was the rapid degradation of native GLP-1. Studies showed that the enzyme dipeptidyl peptidase-4, or DPP-4, cleaved GLP-1 within minutes, giving the native peptide a very short half-life. This observation framed much of the subsequent research effort: how to extend the duration of GLP-1 receptor signaling for sustained study.

From Single Receptor to Multi-Receptor Research

Two broad research strategies emerged to address the half-life problem. One examined molecules that resisted DPP-4 cleavage or otherwise prolonged receptor engagement. Another examined inhibition of the DPP-4 enzyme itself. Both lines of investigation contributed substantially to the metabolic research literature and to the understanding of incretin biology.

As GLP-1 receptor science matured, researchers turned to a more ambitious question. Because GIP, GLP-1, and glucagon are related peptides that act on distinct but complementary receptors, studies began exploring whether a single molecule could engage more than one receptor at once. This work gave rise to dual agonist research, targeting both the GIP and GLP-1 receptors, and then to triple agonist research.

The Triple Agonist Concept

Triple agonists are research compounds designed to engage the GIP, GLP-1, and glucagon receptors simultaneously. The rationale studied in the literature is that combining these signaling pathways may produce metabolic effects that differ from single-receptor engagement. Retatrutide, a triple agonist research compound available for study, exemplifies this multi-receptor approach and is a frequent subject of contemporary metabolic investigation.

The progression from a single gut hormone to engineered multi-receptor molecules captures the arc of the history of GLP-1 research. Each stage built on prior findings, moving from observation of the incretin effect, to peptide discovery, to receptor characterization, to rational design of compounds that act on several receptors at once.

Frequently Asked Questions

When was GLP-1 first discovered in research?

GLP-1 was identified in the 1980s through molecular cloning of the proglucagon gene, when researchers characterized the peptides produced by intestinal processing of the proglucagon precursor.

What is the incretin effect?

The incretin effect, central to the history of GLP-1 research, describes the larger insulin response observed in studies when glucose is taken orally compared with intravenous delivery, attributed to gut-derived hormones such as GIP and GLP-1.

What is a triple agonist?

A triple agonist is a research compound engineered to engage three receptors at once: GIP, GLP-1, and glucagon. Retatrutide is one such triple agonist research compound studied in metabolic literature.

Research Use Disclaimer

This article discusses the history of GLP-1 research and related compounds for research and educational purposes only. All products referenced are sold for laboratory research use only and are not intended for human or veterinary use, diagnosis, treatment, or consumption. Nothing in this article constitutes medical advice or a recommendation regarding any compound.